Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when PT-141 crosses your target, drops, or sets a new tracked low—without daily noise.

Price scopeAlert meTarget per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence229 certificate records mentioning this compound or product name106 provider-linked · 189 exact product matches

Status

FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Research area

Hormone signaling research

Primary research area: Hormone. Also surfaces under Dermal for browsing and discovery.

Aliases

Bremelanotide, Vyleesi

Signal depth

High

FDA label signal · 10 trials · 112 PubMed results

Established

Research evidence

PT-141 is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

PT-141 has 9 name-matched clinical trials (highest phase: Phase 4) and 112 PubMed-indexed publications and holds an FDA drug label. 3 trials have posted results. Note: 1 retracted publication in the literature.

⚠ 1 retracted publication

Human data

Approved drug

Trial quality

Large RCT

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

High-impact

PHASE4Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk PHASE3 · Randomized1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder PHASE3 · Randomized2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Obstetrics and Gynecology · 295 citationsBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder Obstetrics and Gynecology · 198 citationsLong-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder International Journal of Impotence Research · 129 citationsDouble-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What PT-141 is

PT-141 is the research-market name most people use for bremelanotide, a melanocortin peptide that also exists in FDA-approved drug form.

Why it matters

It is a strong example of why peptide names, aliases, and marketed use cases can drift apart. The same underlying compound may be discussed very differently in medical versus vendor contexts.

Regulatory context

Bremelanotide has FDA approval in the United States for a specific labeled use. That does not mean every PT-141 product sold online maps to an approved product or indication.

Practical reading note

Whenever a peptide has both an approved pharmaceutical identity and a research-market nickname, the safest reading starts with the approved label and works outward from there.